Main Menu

Professor Judith Bliss

Deputy Head of Division and Team Leader

The alt text
Professor Judith Bliss is investigating how best to personalise breast cancer treatment for individual patients. She is a member of several national and international research groups, and was recently appointed Vice-Chair of the UK Breast Intergroup. Team: ICR-CTSU Breast and Rare Cancers Trials
0208 722 4297/4013 ORCID 0000-0001-7957-7424


Professor Judith Bliss is Professor of Clinical Trials at The Institute of Cancer Research, London and Director of its Cancer Research UK funded Clinical Trials & Statistics Unit (ICR-CTSU) and Deputy Head of the Division of Clinical Studies.

See all news stories on our website that feature the work of Professor Bliss and colleagues.

Read news

A trials statistician with over 30 years’ experience, her professional interests are in the design and analysis of cancer clinical trials; driven by a desire to ensure that trials are efficient and sufficiently robust to provide both the safety and efficacy results required to directly influence routine clinical practice internationally.

She has been recently awarded a prestigious NIHR Senior Investigator Award recognising her trials leadership, contribution to UK clinical research and the impact of her research on patient outcomes. She has published over 170 peer review papers, largely on breast cancer trials, and has an h-index of 65. She is the statistical lead for numerous trials (including POETIC, TACT2, START, IMPORT, EPHOS, IES) and member of several international trial steering committees (APHINITY, PALLAS, ALTTO, OLYMPIA).

The focus of her work involves trials aimed at maximising benefit in the treatment of breast cancer. This has included work comparing different chemotherapeutic agents and refining radiotherapy schedules as well as optimising the scheduling of endocrine therapy.

Focus for contemporary trial activity is on establishing evidence for biologically targeted therapies through a suite or perioperative window of opportunity trials and more recently trials utilising early biological intermediate endpoints (eg ctDNA analysis) to drive therapeutic choices and predict long term outcomes.

She collaborates with key clinical and scientific opinion leaders and international investigators from Europe and elsewhere via the Breast International Group (REACT –with GBG; MA32 – with NCI-C), via direct bilateral collaborations (PALLET – with NSABP; UNIRAD – with UNICANCER) and with pharmaceutical company partners as required.  

She is currently chair of the UK Breast Intergroup and a member of the UK National Cancer Research Group (NCRI) Breast Clinical Studies Group and recent past chair of its Early Disease Subgroup. Internationally, she is a group representative for the Breast International Group and a member of the Steering Committee for the Early Breast Cancer Trialists Collaborative Group (EBCTCG) and Aromatase Inhibitor Overview Group (AIOG).

She is engaged in research to increase trial efficiency and the challenges of accessing routinely collected data to obtain outcome and survivorship data and was co-chair of the Breast International Group and North American Breast Cancer Group Taskforce on Survivorship.

Professionally trained as a medical statistician (MSc in Medical Statistics & Information Technology from the University of Leicester and Fellow of the UK Royal Statistical Society, her statistical and trial methodology contribution to clinical trials, particularly in breast cancer, was recognised in 2006 with the conferment of the title of Professor in Clinical Trials (University of London).

Now, as a member of the Executive Group of the UK Clinical Research Collaboration Clinical Trials Units Network and Chair of the NCRI Cancer CTU Group she provides leadership across the clinical trials research framework in the UK. Additionally she has considerable experience in grant review committee membership at an international level.

She serves as a member of the Athena SWAN steering group.